Catching up with Keytruda, Regeneron scores frontline NSCLC approval for Libtayo/chemo combo
Regeneron’s Libtayo has made it into the exclusive club of PD-(L) inhibitors approved, in combination with chemotherapy, as a frontline treatment for a broad swath of lung cancer patients.
Based on Phase III overall survival data, the FDA granted Libtayo an approval for the first-line treatment of adult patients with advanced non-small cell lung cancer with no EGFR, ALK or ROS1 aberrations.
“Libtayo is now approved for extending the survival of patients with advanced non-small cell lung cancer as both a monotherapy in high PD-L1 expressors and in combination with chemotherapy irrespective of PD-L1 expression levels, achieving a high bar that has only been met by one other PD-1 targeting agent,” said Israel Lowy, SVP, translational and clinical sciences, oncology at Regeneron.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters